<DOC>
	<DOC>NCT02924233</DOC>
	<brief_summary>This is a phase 1b/2b study investigating the safety and preliminary antitumor effects of Sym004 in combination with nivolumab versus nivolumab monotherapy when administered every second week.</brief_summary>
	<brief_title>Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Main Signed and dated written informed consent Male or female â‰¥18 years of age at the time of informed consent Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Life expectancy &gt;3 months assessed during Screening Histologically or cytologically confirmed, locally advanced or metastatic squamous NSCLC Main Any antineoplastic agent (standard or investigational) within 2 weeks prior to starting trial treatment Radiosurgery or radiotherapy for target lesions within 2 weeks prior to starting trial treatment Prophylactic use of hematopoietic growth factors within 1 week prior to starting trial treatment Active Central Nervous System (CNS) metastases or carcinomatous meningitis Women who are pregnant Women who are breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Squamous</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>